NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 880.1 DKK | -1.96% |
|
-1.16% | +26.20% |
| 03:16pm | News Highlights : Top Company News of the Day - Thursday at 9 AM ET | DJ |
| 02:41pm | Novo Nordisk Lifts Full-Year Sales Outlook as Obesity, Diabetes Drugs Drive First-Quarter Topline Beat | MT |
This Alphavalue article, the European leader in independent research, is only available to subscribers .Alphavalue is exclusively on MarketScreener. To unlock the article, SUBSCRIBE!
Already a customer? Log In
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
01:30am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
897.7
DKK
Average target price
904.2
DKK
Spread / Average Target
+0.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.20% | 571B | |
| +32.16% | 699B | |
| -3.88% | 364B | |
| +18.83% | 326B | |
| +2.90% | 286B | |
| +14.70% | 236B | |
| +4.68% | 198B | |
| -11.94% | 194B | |
| -3.86% | 154B | |
| -3.41% | 149B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk: Novo Nordisk on course to become Europe’s first trillion dollar company?
